kaiser glp-1 coverage 2025 permanente news 📌 Starting January 1, 2025, will be making adjustments to Prescribing GLP-1s: Evidence, limits, expectations

Glucagon-like peptide 1 receptor agonists are not associated with an increased risk of ileus or intestinal obstruction in patients with inflammatory bowel disease: a danish nationwide cohort study

1 g (1,000 mg)

In vitro studies confirm that linagliptin suppresses the proliferation of several tumor cell lines, including colorectal cancer HCT116, breast cancer MCF-7, and liver cancer HepG2, via mechanisms that involve cell cycle arrest and apoptosis induction [96]

Hanlon P, Butterly E, Wei L, Wightman H, Almazam SA, Alsallumi K, et al

For a company with a few hundred employees, that adds up extraordinarily fast regardless of how many people are actually on the medication